Related Funds
| Fund Name | Location |
| Axxon Capital | Boston, Massachusetts, United States |
| Bright Technologies Fund | Lugano, Switzerland, Ticino |
| Capstar Partners | Austin, Texas, United States |
| Climate-KIC Accelerator London | Belgium, Brussels, Brussels Hoofdstedelijk Gewest |
| Faad Network | Delhi, India, New Delhi |
| Fluid Capital Group | - |
| FMC Ventures | Pennsylvania, Philadelphia, United States |
| Heller Financial | Chicago, Illinois, United States |
| Instillo | Germany, Saarland, Überherrn |
| Johnson Family Trust | - |
| Level 5 Capital Partners | Atlanta, Georgia, United States |
| Medina Heights Capital Partners | New York, New York, United States |
| Prisma Energy International | Houston, Texas, United States |
| Rooks Nest Ventures | England, London, United Kingdom |
| Rosalind Advisors | - |
| Seneca Ventures | Seattle, United States, Washington |
| Srikrung Wattana Group | - |
| Steigen | - |
| Yueyou Touzi | China, Hangzhou, Zhejiang |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Aktis Oncology | 30 Sep 2024 | Boston, Massachusetts, United States | |||
858 Therapeutics | $50M | 26 Sep 2024 | San Diego, California, United States | ||
Helaina | $45M | 25 Sep 2024 | New York, New York, United States | ||
MBrace Therapeutics | $85M | 14 Nov 2023 | San Diego, California, United States | ||
Octave | $52M | 15 Jun 2023 | San Francisco, California, United States | ||
Upstream Health | $140M | 02 Dec 2022 | United Kingdom, England, United Kingdom | ||
UpStream Care | $140M | 01 Dec 2022 | Greensboro, North Carolina, United States | ||
Nested Therapeutics | $90M | 06 Oct 2022 | Cambridge, Massachusetts, United States | ||
Prellis Biologics | $35M | 10 Aug 2022 | San Francisco, California, United States |
– GentiBio, Inc. from Boston develops engineered regulatory T cells (Tregs) therapies for immunology.
– Series A $157m round was led by Matrix Capital Management with participation from Avidity Partners, JDRF T1D Fund, OrbiMed, RA Capital Management, and Novartis Venture Fund.
– The company intends to use the funds to advance its potential functional cure for Type 1 Diabetes (T1D) to the clinic alongside multiple other pipeline programs in chronic autoimmunity and autoinflammation.
– Zentera Therapeutics, a Shanghai, China-based clinical-stage biopharmaceutical company, raised $75M in Series B funding.
– The round was led by OrbiMed Advisors Asia and Tybourne Capital Management with participation from Avidity Partners, Casdin Capital, Surveyor Capital, Farallon Capital Management, Lilly Asia Ventures, Logos Capital, Perceptive Advisors, Redmile Group and Viking Global Investors.
– The company intends to use the funds to advance the development of three Zentalis-discovered oncology clinical candidates as well as business development for future pipeline additions in China.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Aktis Oncology | 30 Sep 2024 | Boston, Massachusetts, United States | |||
858 Therapeutics | $50M | 26 Sep 2024 | San Diego, California, United States | ||
Helaina | $45M | 25 Sep 2024 | New York, New York, United States | ||
MBrace Therapeutics | $85M | 14 Nov 2023 | San Diego, California, United States | ||
Octave | $52M | 15 Jun 2023 | San Francisco, California, United States | ||
Upstream Health | $140M | 02 Dec 2022 | United Kingdom, England, United Kingdom | ||
UpStream Care | $140M | 01 Dec 2022 | Greensboro, North Carolina, United States | ||
Nested Therapeutics | $90M | 06 Oct 2022 | Cambridge, Massachusetts, United States | ||
Prellis Biologics | $35M | 10 Aug 2022 | San Francisco, California, United States |
